Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates

January 19, 2017
In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq, which it has partnered with Eisai; spinning out the discovery research activities into a new company, Beacon Discovery; and prioritizing three Phase II programs with readouts in 2017. Munshi updates Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, on the company’s progress to date.
Previous Article
The state of cell and gene therapy: Reimbursement and manufacturing dominate
The state of cell and gene therapy: Reimbursement and manufacturing dominate

The number of cell therapies in clinical trials has grown 21 percent since 2015, with more than 759 trials ...

Next Article
Industry pundit Joe Hage on medtech innovation in 2017
Industry pundit Joe Hage on medtech innovation in 2017

Joe Hage, a medical device marketing consultant, is well known in medtech circles. In particular, he runs o...